 
          Important Notice from CHUGAI PHARMACEUTICAL
ABOUT
We get to the future ahead of the disease.
Chugai is a research and development-oriented pharmaceutical company with unique technology and science as its strengths. In collaboration with Roche, we are committed to continuously generating innovation with the aim of continuously providing patients with innovative drugs and services.
- 
                  *1 Copyright © 2025 IQVIA. Calculated based on JPM 2024. Reprinted with permission. The scope of the market is defined by Chugai. 
- 
                  *2 A system introduced in July 2012 by the U.S. Food and Drug Administration aimed at expediting the development and review of drugs for the treatment of severe or life-threatening diseases or symptoms. 
- 
                  *3 Proportion of sales from products that qualify for premium pricing. (2024) 
- 
            
              INNOVATION We want to eradicate diseases that have no treatments. 
 That is what an innovator should be.
              The three key drivers driving Chugai's growth are RED*Research and Early Development Shift, DX,
              and open innovation.
              We will shift our resources to discovery
              research and early clinical development, which are the source of
              our value creation, apply digital technology to create innovative
              new drugs and increase efficiency in the value chain, and actively
              collaborate with external partners.
            
* Research and Early Development
The purpose of innovation, R&D efforts, and results
 
            SUSTAINABILITY
                    Putting sustainability at the heart of our business
Creating shared value with Society and developing together
                  
                Stories
            Creating Continuous Innovation.
            The Story of Our Challenges
          
        UPDATE
Latest Information
- 
                                                                                      
                
                Announcing the renewal of the Chugai Recruiting Site 
- 
                                                                                      
                
                We have reached our 100th anniversary 
- 
                                                                                      Announcing the renewal of the Website 
- 
                                                                                                                  
                  
                  Script (including Q&A) for Conference on FY2025.12 Q3 Financial Results 
- 
                                                                                                                  
                  
                  The dates of the Financial Results for 2025 FY, 2026 Q1, Q2, and Q3 have been updated. 
- 
                                                                                                                  
                  
                  Conference on FY 2025.12 Q3 Financial Results 
- 
                                                                                                                  
                  
                  Financial Results for Third Quarter of Fiscal Year 2025 (Jan-Sep 2025) 
- 
                                                                                                                  
                  
                  Events & Presentations has been updated with the Date of Sustainability Meeting 
Chugai News Releases are issued to provide stakeholders with the most up-to-date information related to our company. In some instances, information on products or drug candidates under development may be included, but this is intended for members of the media, shareholders, and investors. The information is not intended for promotional or advertising purposes, or as medical advice, etc.
- 
                                        
                                    
                Roche Announces Global Phase III INShore Study Topline Results on Gazyva for Idiopathic Nephrotic Syndrome in Children and Young Adults 
- 
                                        
                                    
                Chugai Announces 2025 3rd Quarter Results 
- 
                                        
                                    
                Notice Concerning Making Renalys Pharma, Inc. a Wholly-Owned Subsidiary 
- 
                                        
                                    
                F. Hoffmann-La Roche Announces Third Quarter Sales 2025 
- 
                                        
                                    
                Alecensa Extends Median Overall Survival to Over 80 Months in ALK-Positive Metastatic Non-Small Cell Lung Cancer 
 
             
                 
                         
                         
                         
                         
                             
                             
                             
                             
                             
                             
                             
                             
                             
                             
                             
                             
                             
                             
                            